Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
出版年份 2014 全文链接
标题
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
作者
关键词
Dipeptidyl peptidase-4 inhibitor, Major adverse cardiovascular events, Saxagliptin, Type 2 diabetes mellitus
出版物
Cardiovascular Diabetology
Volume 13, Issue 1, Pages 33
出版商
Springer Nature
发表日期
2014-02-04
DOI
10.1186/1475-2840-13-33
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
- (2013) Yao Dai et al. ACTA DIABETOLOGICA
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus
- (2013) Susana Ravassa et al. Cardiovascular Diabetology
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes
- (2013) J. Rosenstock et al. DIABETIC MEDICINE
- CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
- (2013) Sang Ah Lee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular effects of gliptins
- (2013) André J. Scheen Nature Reviews Cardiology
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
- (2013) Joel M. Neutel et al. Diabetes Therapy
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Heart Disease and Stroke Statistics—2013 Update
- (2012) Alan S. Go et al. CIRCULATION
- Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study
- (2012) Michel P. Hermans et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
- (2012) Anthony H. Barnett et al. CURRENT MEDICAL RESEARCH AND OPINION
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial
- (2012) Robert Frederich et al. Diabetology & Metabolic Syndrome
- Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
- (2011) Antonio R Chacra et al. Diabetes & Vascular Disease Research
- Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
- (2011) Priscilla L Hollander et al. Diabetes & Vascular Disease Research
- Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up: Lessons from the San Luigi Gonzaga Diabetes Study
- (2011) F. Cavalot et al. DIABETES CARE
- Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
- (2011) A. Pfützner et al. DIABETES OBESITY & METABOLISM
- Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes
- (2011) R. R. Henry et al. DIABETES OBESITY & METABOLISM
- Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
- (2011) M. Nowicki et al. DIABETES OBESITY & METABOLISM
- Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
- (2011) V. Fonseca et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial
- (2011) Wenying Yang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
- (2011) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin
- (2010) Kaj Stenlöf et al. CURRENT MEDICAL RESEARCH AND OPINION
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Intensive glucose control and macrovascular outcomes in type 2 diabetes
- (2009) F. M. Turnbull et al. DIABETOLOGIA
- Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
- (2009) A. R. Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
- (2009) Priscilla Hollander et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started